No Data
No Data
Cinda Securities released a research report on April 23 stating that it gave Langzi Shares (002612.SZ) a purchase rating. The main reasons for the rating include: 1) the steady increase in revenue/profitability of the medical and aesthetic sector; 2) the
Cinda Securities released a research report on April 23 stating that it gave Langzi Shares (002612.SZ) a purchase rating. The main reasons for the rating include: 1) the steady increase in revenue/profitability of the medical and aesthetic sector; 2) the women's clothing direct sales & online channels have achieved excellent growth; 3) the infant potential circuit continues to grow steadily, and the domestic market may be an important growth engine in the future; 4) continuous optimization on the rate side drives a significant increase in profitability. (Mainichi Keizai Shimbun)
Langzi Co., Ltd. (002612): Performance is in line with expectations, and the company continues to grow with high quality
Introduction to this report: All three businesses achieved rapid growth in 2023, and the company's net profit to mother increased 953% year over year; in 2024, the company will continue to promote endogenous and epitaxial expansion, and performance flexibility is expected to continue to be unleashed. Key investment points: investment and construction
Langzi Co., Ltd. (002612): Medical and aesthetic revenue increased 28% in '23, profitability recovered year on year
The 2023 results are in line with the previous forecast range, in line with our expectations. The company announced 2023 results: revenue of 5.145 billion yuan, +24.4% year-on-year after adjustment (same below); net profit of 225 million yuan (vs22)
Langzi Co., Ltd. (002612): Endogenous extension simultaneously helps medical and aesthetic growth and nurtures stores are expected to gradually reduce losses
The core view is that after retroactive adjustments were made to the merger of Wuhan Han Chen and Wuhan Wuzhou, the company's revenue in 2023 was +24.41%, of which the medical and aesthetic business was +27.8%, and endogenous extension simultaneously boosted revenue. At the same time, the company plans to share every 10 shares
Langzi Co., Ltd. (002612): Net profit due to mother increased 953% in 2023, medical and aesthetic business further expanded the chain layout
Seizing the opportunities for consumer recovery, the performance was good in 2023. The company achieved revenue of 5.145 billion yuan in 2023, an increase of 24.41% year on year, and net profit of 225 million yuan to mother, an increase of 953.37% year on year, less
Langzi Co., Ltd. (002612.SZ) announced its 2023 annual results, with net profit of 225 million yuan, an increase of 953.37%
Langzi Co., Ltd. (002612.SZ) released its 2023 annual report. During the reporting period, the company achieved an operating income of 5...
No Data